US20170182092A1 - Multicomponent oral care composition - Google Patents
Multicomponent oral care composition Download PDFInfo
- Publication number
- US20170182092A1 US20170182092A1 US15/229,757 US201615229757A US2017182092A1 US 20170182092 A1 US20170182092 A1 US 20170182092A1 US 201615229757 A US201615229757 A US 201615229757A US 2017182092 A1 US2017182092 A1 US 2017182092A1
- Authority
- US
- United States
- Prior art keywords
- care composition
- oral care
- fluoride
- composition according
- apatite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 53
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims abstract description 50
- 239000000606 toothpaste Substances 0.000 claims abstract description 36
- 229940034610 toothpaste Drugs 0.000 claims abstract description 34
- 229940051866 mouthwash Drugs 0.000 claims abstract description 33
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 27
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 26
- 238000009472 formulation Methods 0.000 claims abstract description 21
- 239000002324 mouth wash Substances 0.000 claims abstract description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 18
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 14
- 210000000214 mouth Anatomy 0.000 claims abstract description 13
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 201000002170 dentin sensitivity Diseases 0.000 claims abstract description 9
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 5
- 229940041678 oral spray Drugs 0.000 claims abstract description 4
- 239000000668 oral spray Substances 0.000 claims abstract description 4
- 229940085991 phosphate ion Drugs 0.000 claims abstract description 4
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 64
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical class [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 47
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 46
- 229910052586 apatite Inorganic materials 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 26
- 229910052587 fluorapatite Inorganic materials 0.000 claims description 23
- 229940077441 fluorapatite Drugs 0.000 claims description 23
- 239000011575 calcium Substances 0.000 claims description 20
- -1 polyoxyethylene Polymers 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- 229910019142 PO4 Inorganic materials 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229910052712 strontium Inorganic materials 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminium flouride Chemical compound F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 4
- 229910001634 calcium fluoride Inorganic materials 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011775 sodium fluoride Substances 0.000 claims description 3
- 235000013024 sodium fluoride Nutrition 0.000 claims description 3
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- DAOANAATJZWTSJ-UHFFFAOYSA-N N-Decanoylmorpholine Chemical compound CCCCCCCCCC(=O)N1CCOCC1 DAOANAATJZWTSJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- KVBCYCWRDBDGBG-UHFFFAOYSA-N azane;dihydrofluoride Chemical compound [NH4+].F.[F-] KVBCYCWRDBDGBG-UHFFFAOYSA-N 0.000 claims description 2
- GFIKIVSYJDVOOZ-UHFFFAOYSA-L calcium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical class [Ca+2].[O-]P([O-])(F)=O GFIKIVSYJDVOOZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- SAEOCANGOMBQSP-UHFFFAOYSA-N diazanium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical class [NH4+].[NH4+].[O-]P([O-])(F)=O SAEOCANGOMBQSP-UHFFFAOYSA-N 0.000 claims description 2
- FXNRKXSSLJKNGH-UHFFFAOYSA-L dipotassium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical class [K+].[K+].[O-]P([O-])(F)=O FXNRKXSSLJKNGH-UHFFFAOYSA-L 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- KMXTYZBQPJXGNK-UHFFFAOYSA-N hexadecan-1-amine;hydron;fluoride Chemical compound F.CCCCCCCCCCCCCCCCN KMXTYZBQPJXGNK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000392 octacalcium phosphate Inorganic materials 0.000 claims description 2
- LXPCOISGJFXEJE-UHFFFAOYSA-N oxifentorex Chemical compound C=1C=CC=CC=1C[N+](C)([O-])C(C)CC1=CC=CC=C1 LXPCOISGJFXEJE-UHFFFAOYSA-N 0.000 claims description 2
- 239000011698 potassium fluoride Substances 0.000 claims description 2
- 235000003270 potassium fluoride Nutrition 0.000 claims description 2
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 2
- VAWSWDPVUFTPQO-UHFFFAOYSA-N calcium strontium Chemical compound [Ca].[Sr] VAWSWDPVUFTPQO-UHFFFAOYSA-N 0.000 claims 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 abstract description 14
- 208000028169 periodontal disease Diseases 0.000 abstract description 6
- 208000007565 gingivitis Diseases 0.000 abstract description 5
- 230000008859 change Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 210000005239 tubule Anatomy 0.000 description 42
- 229940091249 fluoride supplement Drugs 0.000 description 39
- 210000003298 dental enamel Anatomy 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 239000013078 crystal Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000004268 dentin Anatomy 0.000 description 9
- 238000001878 scanning electron micrograph Methods 0.000 description 9
- 238000005115 demineralization Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940074371 monofluorophosphate Drugs 0.000 description 7
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000001680 brushing effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 235000010492 gellan gum Nutrition 0.000 description 3
- 239000000216 gellan gum Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 238000004319 19F solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004673 fluoride salts Chemical class 0.000 description 2
- 239000010436 fluorite Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 229960004029 silicic acid Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- 239000001278 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol Substances 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Chemical group CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Chemical group CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical group [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- ZBJCYZPANVLBRK-UHFFFAOYSA-N Menthone 1,2-glyceryl ketal Chemical compound CC(C)C1CCC(C)CC11OC(CO)CO1 ZBJCYZPANVLBRK-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- MXKIASVYJZPUMJ-UHFFFAOYSA-N S.SC Chemical compound S.SC MXKIASVYJZPUMJ-UHFFFAOYSA-N 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004763 bicuspid Anatomy 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- NKCVNYJQLIWBHK-UHFFFAOYSA-N carbonodiperoxoic acid Chemical compound OOC(=O)OO NKCVNYJQLIWBHK-UHFFFAOYSA-N 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical group FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to a multicomponent oral health care composition that can be used as a toothpaste, oral spray or a mouth wash/oral rinse formulation.
- the different components in the composition act synergistically together to clean the teeth and mucous membranes of an oral cavity of a subject, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct unpleasant odours. They achieve this by inhibiting caries, promoting teeth remineralisation, and helping to alleviate dentine hypersensitivity, gingivitis and periodontal disease.
- Tooth mineral in humans and animals is based on calcium apatite, Ca 5 (PO 4 ) 3 OH.
- Natural tooth apatites are heavily solid substituted, and the Ca 2+ cations in the crystal lattice may be replaced by, for example, Sr 2+ , Mg 2+ or Zn 2+ , or by two Na + cations.
- the phosphate (PO 4 ) 3 ⁇ anions may be replaced by carbonate ions (CO 3 2 ⁇ ), with an associated Na + cation replacing a Ca 2+ cation or the associated loss of a hydroxyl ion (OH ⁇ ).
- the hydroxyl ion may also be replaced by a fluoride ion (F ⁇ ).
- plaque that forms on teeth as a result of the activity of bacteria is not completely removed by the act of brushing teeth.
- the plaque may act as a reservoir for fluoride in the mouth, where it is thought to form fluorite-like species, such as calcium fluoride (CaF 2 ).
- fluorite-like species such as calcium fluoride (CaF 2 ).
- the accumulation of dental plaque biofilms, whilst it may possibly be desirable as a fluoride reservoir, is also the source of the acid-producing bacteria that cause caries and gingivitis, which can progress to become periodontal disease. Their presence is therefore undesirable.
- fluoride becomes integrated within the hydroxyapatite crystals, creating enlarged and less soluble crystals.
- Salivary flow rates vary enormously from individual to individual and vary during the course of the day, reducing almost to zero during sleep. Salivary flow rates are typically about 0.25 to 1.2 ml/min during the day, while the salivary volumes are typically about 1-10 ml. Additionally, salivary flow rates are observed to reduce with age and with smoking.
- the plaque acts as a barrier to fluoride uptake.
- fluoride uptake into enamel is extremely rapid. It is important to note that remineralisation requires a source of both Ca 2+ and PO 4 3 ⁇ ions in addition to fluoride in order to form fluorapatite.
- Fluoride is proposed to enhance the precipitation of fluorapatite crystals in solutions containing calcium and phosphate and therefore tends to prevent the demineralisation of teeth.
- Evidence has linked fluorite to enhancing iron absorption.
- the calcium and phosphate may come from the saliva itself.
- F ⁇ , Ca 2+ , and PO 4 3 ⁇ within the toothpaste itself.
- This may be provided by soluble forms of F ⁇ , Ca 2+ , and PO 4 3 ⁇ , or more preferably particulate, sparingly soluble forms that give rise to controlled release of calcium and phosphate as a result of the particles adhering to the teeth and gingivae and slowly dissolving.
- examples include bioactive glasses, and particularly hydroxyapatite.
- VSC volatile sulphur compounds
- HSC volatile sulphur compounds
- peptones proteins found in the oral cavity of a human or animal subject.
- substrates are readily available in saliva and dental plaque, or may be derived from proteinaceous food particles, as well as exfoliated oral epithelium food debris.
- Stabilised chlorine dioxide is an aqueous solution containing chlorite ions and stabilisers.
- the stabilisers may comprise, for example, a carbonate or bicarbonate buffering system.
- the chlorine dioxide has bacteriocidal and bacteriostatic effects on the bacteria in the oral cavity of a human or animal subject.
- Stabilised chlorine dioxide reacts with the cell walls of microorganisms (changing the proteins and fats in the cell wall membrane), acts as a strong oxidising agent (oxidising the polysaccharide matrix that keeps the biofilm together) and effectively kills pathogenic microorganisms such as fungi, bacteria and viruses.
- Chlorine dioxide has a well proven role in destroying the bacteria involved in plaque formation, caries, gingivitis and periodontal disease, as well as eliminating halitosis. As chlorine dioxide destroys the plaque-forming bacteria, it is particularly effective in plaque removal, in conjunction with physical tooth brushing. Removal of this plaque will remove the physical barrier to fluoride, calcium and phosphate ions being able to reach the demineralised tooth surface, and thus promotes and enhances remineralisation of the tooth surface.
- an oral care composition comprising:
- the source of a fluoride ion is typically a soluble fluoride salt.
- exemplary sources of fluoride ions which are envisaged by the present invention include, but are not limited to, sodium fluoride, potassium fluoride, disodium monofluorophosphate, tin (II) fluoride (stannous fluoride), dipotassium fluorophosphates, calcium fluorophosphates, calcium fluoride, ammonium fluoride, aluminium fluoride, hexadecyl ammonium fluoride, 3-(N-hexadecyl-N-2-hydroxy-ethylammonio) ammonium difluoride, N,N′,N′-Tris(polyoxyethylene)-N-hexadecyl-propylenediaminedihydrofluoride disodium hexafluorosilicate, dipotassiumhexafluorosilicate, ammonium hexafluorosilicate
- the source of fluoride ions has a concentration of fluoride between about 20 and about 1500 ppm as fluorine.
- the source of fluoride ions may have a concentration in the range of between about 0.1% to about 3.0% (w/v) in the oral care composition, typically between about 0.25% to about 2.0% (w/v), more typically between about 0.50% to about 1.5% (w/v), still more typically between about 1.00% to about 1.2% (w/v).
- both the calcium ions and the phosphate ions are typically provided by an apatite species, such as a nano-crystalline apatite.
- Nano-crystalline is defined herein as where the crystallites have a size of less than about 100 nm.
- the crystallite sizes of the apatites are determined from X-ray diffraction line width data using the Scherrer Line broadening method.
- the width at half height of the 002 reflection ⁇ 002 is inversely proportional to crystallite length in the c-axis direction (Cullity 1956) and is given by the equation:
- D is the crystallite size in nm; ⁇ is the wavelength of the incident X-rays, 0.154 nm; ⁇ 002 is the width at half height of the 002 reflection and cos ⁇ is the cosine of the X-ray incident angle (25.85°).
- the 002 reflection is a term well known to a person skilled in the art, and is explained in, for example, the textbook ‘Elements of X-Ray Diffraction’, (3rd Edition); B. D. Cullity (2001); Addison-Wesley Chapter 2; ISBN-10: 0201610914.
- the composition contains an appropriate buffering system.
- buffer systems which are envisaged by the present invention include, but are not limited to, those comprising one or more of acetate, carbonate, citrate or phosphate salts.
- the oral care composition may be contained within, for example, a toothpaste, oral spray or a mouth wash/oral rinse formulation, or in any other formulation which may be used for the improvement of oral hygiene.
- a toothpaste, oral spray or a mouth wash/oral rinse formulation or in any other formulation which may be used for the improvement of oral hygiene.
- Such formulations will of course be readily apparent to a person skilled in the art.
- the oral care composition of the invention is able to achieve remineralisation of incipient caries lesions much more effectively than when the components therein are utilised individually or separately.
- the fluoride source provides fluoride ions for forming fluorapatite, whilst the hydroxyapatite can provide both the calcium and phosphate ions, and the chlorine dioxide kills the bacteria forming the plaque.
- Use of this composition substantially eliminates the plaque and facilitates the uptake of Ca 2+ , PO 4 3 ⁇ and F ⁇ ions into the tooth structure and enables remineralisation to occur.
- the effect of the composition is further enhanced when employed in combination with physical brushing of the teeth.
- the apatite is based on the formula M 5 (PO 4 ) 3 X, wherein M may be Ca, Sr, Zn or Mg, and X may be F, Cl or OH.
- Specific apatite compounds used in accordance with the invention may therefore include, but are not limited to, substituted or unsubstituted hydroxyapatites, substituted or unsubstituted fluorapatites, or substituted or unsubstituted hydroxycarbonated apatites, such as calcium hydroxyapatite, strontium hydroxyapatite, calcium hydroxycarbonated apatite, strontium hydroxycarbonated apatite, calcium fluorapatite, strontium fluorapatite, mixed strontium/calcium apatites or a mixed hydroxyfluorapatite, zinc substituted hydroxyapatite, zinc carbonated hydroxyapatite, zinc fluorapatite, or octacalcium phosphate.
- the stabilised chlorine dioxide solution may have a concentration in the range of between about 0.05% to about 2.0% (w/v) in the oral care composition, typically between about 0.075% to about 1.0% (w/v), more typically between about 0.10% to about 0.5% (w/v), still more typically between about 0.12% to about 0.2% (w/v), and/or may have a pH or be buffered to a pH of between about 6.0 and about 8.0, typically between about 7.0 and about 8.0.
- the source of fluoride ions may have a fluoride ion concentration of between about 300 ppm and about 1500 ppm.
- the source of fluoride ions may have an active fluoride ion concentration of between about 5 and about 500 ppm.
- active fluoride ion concentration is meant the amount of fluoride ion that is free and available for reaction and involvement in the remineralisation process. Depending upon the fluoride ion source used, this may be less than the total fluoride ion concentration in the overall oral composition.
- a stabilised chlorine dioxide solution in combination with a source of calcium ions, a source of phosphate ions and a source of fluoride ions, to generate gaseous chlorine dioxide within the oral cavity without the use of extra oral sources of acidification.
- the calcium ions and phosphate ions may be provided together by an apatite species as detailed hereinabove.
- the apatite may be present in an amount of from about 0.5 to about 30 weight percent of the oral care composition.
- the apatite may have a particle size distribution such that at least about 3% of the mass of the particles have a size less than about 5 microns and where the apatite has a crystallite size of less than about 200 nm.
- the apatite may be present in an amount of from about 0.5 to about 25 weight percent of the composition.
- the apatite particle size distribution may have at least about 15% of the mass of the particles below about 5 microns and where the apatite crystallite size is from about 30 to about 50 nm.
- the apatite may be present from about 0.5 to about 15 weight percent of the composition.
- at least about 50% of the mass of the particles may have a particle size less than about 5 microns.
- composition of the invention may also contain other components selected from one or more of a solvent, a thickening agent or viscosity modifier, an abrasive, a flavour, an aromatic component, a humectant, a sweetener, a carrier, a remineralising agent, a film forming agent, a buffering agent, a cooling agent, a pH adjusting agent, an oxidizing agent, and a colorant.
- Exemplary such compounds which may be added to the composition of the invention may include, but are not limited to, glycerol, water, hydrated silica, cellulose gum, trisodium phosphate, sodium saccharin, mentha extracts, citric acid, limonene, linalool, and titanium dioxide.
- this formulation may also comprise a linear polysaccharide polymer with a high yield value that exhibits pseudoplastic flow to stabilise the HA in suspension.
- a linear polysaccharide gum where one or more hydroxyl groups on the monosaccharide is substituted with a functional group that comprises a carboxyl group (R—COOH), an acyl group (RCO—) or a sulphate group (R—OSO 3 ⁇ ) is used.
- R—COOH carboxyl group
- RCO— acyl group
- R—OSO 3 ⁇ sulphate group
- a second aspect of the invention deals with dentine hypersensitivity.
- Dentine hypersensitivity is felt when nerves inside the dentin of the teeth are exposed, and results in pain associated with mechanical stimuli, such as that caused by the intake of hot or cold foodstuffs into the mouth. This typically affects more than 40% of the population. It is a result of fluid flow in exposed open dentinal tubules that results in pressure changes that trigger nerve transmission within the pulp chamber of a tooth. Dentinal tubules become exposed as a result of three causes:
- Treatment generally involves sealing or blocking the dentinal tubules. This is often achieved using specialised toothpastes that are designed to occlude the dentinal tubules.
- the dentinal tubule openings are typically about 2-5 microns in diameter.
- tubules can be blocked is to precipitate a material onto the surface over the top of the tubules.
- Another approach i.e. that used by the present invention, is to have particles comparable in size to the openings of the dentinal tubules, so the particles are able to enter into the tubules and occlude them. It is important that there are sufficient particles of the required size present to give effective numbers penetrating the dental tubules.
- an oral care composition as defined herein above in the remineralisation of teeth or in the treatment of dentine hypersensitivity.
- a method of cleaning teeth and mucous membranes of the oral cavity of a subject, or perfuming them or protecting them in order to keep them in good condition comprising applying an oral care composition as defined hereinabove.
- the apatite may be present in an amount of from about 0.5 to about 30 weight percent of the oral care composition.
- the apatite may have a particle size distribution such that at least about 3% of the mass of the particles have a size less than about 5 microns and where the apatite has a crystallite size of less than about 200 nm.
- the apatite may be present in an amount of from about 0.5 to about 25 weight percent of the composition.
- the apatite particle size distribution may have at least about 15% of the mass of the particles below about 5 microns and where the apatite crystallite size is from about 30 to about 50 nm.
- the apatite may be present from about 0.5 to about 15 weight percent of the composition.
- at least about 50% of the mass of the particles may have a particle size less than about 5 microns.
- a toothpaste comprising an oral care composition of the invention as defined hereinabove.
- the apatite species in the toothpaste such as a nano-crystalline hydroxyapatite, comprises small crystallites having a size of less than about 100 nm and a large surface area to facilitate dissolution.
- the larger particles which can occlude the dentinal tubules comprise many hundreds of crystallites aggregated together to form an approximately spherical particle with dimensions in the range 0.1 to 5 microns, and thus are similar in size to the openings to the dentinal tubules.
- Table 1 summarises the particle size data from a range of nano-crystalline hydroxyapatites in terms of the D10, D50 and D90 values which represent the volume fractions below the specified values. It can be seen from the particle sizes in the Table that they are of a similar size to the openings to the dentinal tubules, and are therefore able to occlude dentinal tubules.
- FIG. 1 shows a scanning electron micrograph of open dentinal tubules.
- FIG. 2 shows a scanning electron micrograph of dentinal tubules being blocked by precipitate of a material over the top of the tubules.
- FIG. 3 shows a scanning electron micrograph of acid-etched dentine.
- FIG. 4 shows a scanning electron micrograph of dentinal tubules following blocking with a composition according to the invention.
- FIG. 5 shows the crystal structure of hydroxyapatite.
- FIG. 6 shows X-ray powder diffraction patterns of a nano-crystalline hydroxyapatite (nHA) and of a micro-crystalline hydroxyapatite.
- FIG. 7 a shows an etched dentine surface of a mid-coronal section of a human molar.
- FIG. 7 b shows a mucin-coated dentine surface to mimic biofilm.
- FIG. 7 c shows a tooth surface after treatment with a chlorine dioxide toothpaste according to the invention, but containing silica powder instead of hydroxyapatite.
- FIG. 8 shows the hardness values of the tooth surface of the molars after applying a toothpaste according to the invention.
- FIG. 9 shows NMR spectra for enamel samples; non-treated, demineralised and treated with a toothpaste according to the invention.
- FIG. 10 shows NMR spectra for enamel samples non-treated, demineralised and treated with a mouth wash according to the invention.
- FIG. 11 shows a graph illustrating the amount of total fluoride in a mouth wash according to the invention in relation to the amount of active, or free, fluoride available for remineralisation.
- FIG. 12 shows a graph illustrating the enamel weight loss during the demineralisation and treatment with a toothpaste according to the invention.
- FIG. 13 shows a scanning electron micrograph of a dentine surface of a specimen treated for 1 day with a mouth wash according to the invention (4 ⁇ 2 minutes of treatment, followed by remineralisation).
- FIG. 14 shows a graph illustrating reduction in fluid flow through dentinal tubules following tooth brushing with a toothpaste according to the invention.
- FIG. 1 shows a scanning electron micrograph of open dentinal tubules.
- One way these tubules can be blocked is to precipitate a material onto the surface over the top of the tubules.
- FIG. 2 depicts a material (in this instance, Colgate ProRelief) over the top of the tubules. As can be seen, not many of the openings of the tubules are blocked.
- FIG. 3 shows a scanning electron micrograph of acid etched dentine, i.e. a molar tooth cut through the mid coronal section, which has been acid etched using 6% citric acid for 2 minutes.
- the tubules are clearly visible.
- the scanning electron micrograph in FIG. 4 shows these same tubules after a composition according to the invention comprising 7.5 wt % hydroxyapatite has been applied to the tooth. It can be seen that the dentinal tubules are substantially blocked by the particles in the composition, thus preventing the fluid flow through the dentinal tubules and minimising pain for the subject.
- FIG. 6 there is a comparison between the X-ray powder diffraction patterns of a nano-crystalline hydroxyapatite (nHA) and of a larger microcrystalline hydroxyapatite. It can be seen that the diffraction pattern of the nHA shows pronounced line broadening compared with that of the microcrystalline hydroxyapatite. Using Sherrer line broadening analysis, the nHCA has a crystallite size of 30 to 50 nm.
- purified water BP is added and stirring commences.
- Sodium saccharin, trisodium phosphate and sodium monofluorophosphate are added and allowed to dissolve.
- Glycerin and cellulose gum are premixed thoroughly and added to the main vessel using high shear mixing.
- Hydrated silica, hydroxyapatite and titanium dioxide are added and mixed under high shear until a smooth homogenous paste is created.
- the vessel has a jacket which is cooled with chilled water to ensure the contents remain below 40° C.
- Menthol, peppermint oil BP & spearmint oil BP are premixed in a separate vessel to create the flavour blend. This is subsequently added to the paste in the main vessel with mixing.
- Chlorine dioxide 5% solution (proprietary blend) is added to the paste with mixing, and the pH of the paste is adjusted to comply with the specification using a citric acid/purified water BP premix and adequate stirring.
- the final toothpaste formulation contains 1250 ppm of chlorine dioxide, 10900 ppm of sodium monofluorophosphate (which equates to 1428 ppm of fluoride in the monofluorophosphate, calculated by using the respective atomic and molecular weights of fluorine and sodium monofluorophosphate, which are 19 and 145, respectively), and 75000 ppm of hydroxyapatite.
- purified water BP/EP is added and is heated to 80° C. ( ⁇ 5° C.,). The water is then stirred and recirculated through an in-line high shear homogeniser.
- Kelcogel HA high acyl content gellan gum a polysaccharide consisting of glucose, rhamnose, and glucuronic acid repeat units and with a substituent glycerate moiety on every glucose unit and an acetate moiety on every second glucose moiety
- Cekol 4000 a carboxymethyl cellulose polymer, used to minimise flocculation and aid bioadhesion
- sodium monofluorophosphate is then added to the vessel, followed by sodium citrate, trisodium citrate and sodium saccharin.
- the introduction of Na + ions to the mixture causes the high acyl content gellan gum to thicken and form a fluid, highly mobile gel. The mixing and homogenising is continued.
- a flavour pre-mix is prepared by adding polysorbate 20, PEG-60 hydrogenated castor oil, Frescolat MGA and Coolmint FL72627. These components are mixed thoroughly until a clear solution is obtained.
- Citric acid is then added, and the mixture is allowed to mix for a further 15 minutes, to ensure that the pH of the product is 8.0-8.5. The homogenising and stirring then ceases, and the resultant product is protected from exposure to sunlight.
- the final mouth wash or oral rinse formulation contains 1250 ppm of chlorine dioxide, 5000 ppm of sodium monofluorophosphate (which equates to 655 ppm of fluoride in the monofluorophosphate, again calculated by using the respective atomic and molecular weights of fluorine and sodium monofluorophosphate), and 50000 ppm of hydroxyapatite.
- One of the key aspects of the present invention is the use of chlorine dioxide combined with the use of an apatite and fluoride.
- the chlorine dioxide role in the formulation is to remove plaque and biofilm from the tooth surface and particularly from exposed dentine surfaces; this serves to open the dentinal tubules and facilitates the subsequent occlusion of the dentinal tubules by the apatite particles.
- Chlorine dioxide fulfils the same purpose within the toothpaste or oral rinse.
- FIG. 7 a shows an SEM of a mid-coronal section of a human molar treated with 6% citric acid for 2 minutes to open the dentinal tubules then painted with a 2.5% solution of mucin, a common salivary protein, air dried and then followed by a stabilisation treatment with 10% formalin solution. The process was repeated to produce a water stable protein biofilm. It can be seen ( FIG. 7 b ) that following treatment the tubules are occluded with the biofilm. A toothpaste where the occluding agent in the formulation, hydroxyapatite, is replaced by silica powder was then applied to the tooth surface for 2 minutes, followed by rinsing with distilled water. It can be seen ( FIG.
- One of the key aspects of the invention is the ability of the apatite to work in conjunction with a source of fluoride to promote remineralisation. This is particularly important with regard to replacing lost tooth mineral due to acid erosion, incipient caries, or to promote the conversion of the apatite occluding the dentinal tubules to more durable fluoridated apatite. This is illustrated by two techniques:
- F in kilogram-force (kgf)
- A is the area of the point of the indenter
- d is the average length of the diagonal left by the indenter in millimeters.
- FIG. 8 shows the hardness values. Following the acid challenge the hardness decreases significantly, but increases significantly after exposure to the toothpaste providing clear evidence of remineralisation.
- Caries-free first molar and premolars were collected and stored in 3% sodium hypochlorite solution for 24 hours. Teeth were mounted in acrylic resin, and sliced using an annular diamond blade (Microslice 2, Malvern Instrument, UK) to get enamel sections (approximately 6 ⁇ 5 ⁇ 1 mm 3 ). Excess dentine area was removed by polishing against P600 silicon carbide paper.
- Enamel samples (no treatment, 24 hours demineralised and demineralization followed by the treatments) were ground to powder using a vibratory mill (MM200, Glen Creston Ltd, UK) with a 25 ml zirconia grinding jar for 15 seconds under 20 Hz. The powder was then used for solid-state NMR experiments using the 600 MHz (14.1 T) Bruker spectrometer. The 19 F solid state NMR measurements were run at the resonance frequency of 564.7 MHz with a 2.5 mm rotor spun at 18 and 21 kHz. Spectra were obtained by overnight scans with 8 preliminary dummy scans and 60 seconds recycling delay. The chemical shift was referenced using the signal from the 1M NaF solution scaled to ⁇ 120 ppm relative to the CF 3 Cl primary standard.
- the NMR spectra showed flat lines for both the non-treated enamel sample and the demineralised enamel sample ( FIGS. 9 and 10 ). Therefore, there was no fluoride detected for both samples. This indicated that no significant fluoride was present in the original tooth samples.
- the spectra were then run for the toothpaste and oral rinse samples.
- the toothpaste with both HA and monofluorophosphate (MFP) showed the presence of fluorapatite with a chemical shift of ⁇ 103 ppm, the position being almost identical to the chemical shift of the fluorine in fluorapatite ( ⁇ 102 ppm), as did the toothpaste with MFP alone treated samples.
- the HA toothpaste alone gave a very small signal close to that of fluorite, which was probably present in the original tooth.
- the oral rinse treated enamel sample showed a broad peak centered at around ⁇ 103 ppm, This demonstrates that after demineralisation treatment, the Ultradex Recalcifying and Whitening Toothpaste and Oral Rinse treatment of the invention led to fluorapatite formation.
- the reference spectrum for the fluorapatite was based on synthetic pure fluorapatite, which demonstrates a distinct sharp peak with a chemical shift at ⁇ 102 ppm.
- the apatite that comprises the tooth enamel is a solid solution formed rather than stoichiometric.
- Fluoride promotes remineralisation and the fluorapatite formed is more acid resistant compared with the hydroxyapatite and carbonated hydroxyapatite.
- high concentrations of fluoride with insufficient phosphate ions may result in the formation of the undesirable calcium fluoride phase.
- An Ultradex Recalcifying and Whitening Oral Rinse/mouth wash of the invention contains 660 ppm F ⁇ in the form of monofluorophosphate, with a 1:2 dilution, the total available F ⁇ was 330 ppm.
- the actual available F ⁇ detected by a fluoride selective electrode (ORION 9609BN PH/ISE meter model 710 A, USA) ( FIG. 11 ) was only 24.5 ppm.
- the F ⁇ after the remineralisation was 19.5 and this gave an F ⁇ loss of 5 ppm. This further confirms fluoride is being incorporated into the apatite.
- the scanning electron micrograph in FIG. 13 clearly demonstrates that a tooth specimen that is treated over a period using the mouth wash of the invention—in this case over 1 day, with 4 lots of 2 minutes' worth of treatment with the mouth wash, followed by the remineralisation—achieves the aim of successfully occluding the dentinal tubules, and thus reduce dentine hypersensitivity.
- FIG. 14 it can be seen from the graph that there is a reduction in fluid flow through dentinal tubules following tooth brushing with a toothpaste according to the invention, thus indicating that the tubules have been successfully blocked by the action of the fluoride in the remineralisation process. This is a test that is routinely used as a measure of the efficacy of a hypersensitivity toothpaste.
- composition of the invention provides technical advantages over existing formulations lacking any one of the defined components.
- Application to the surface of teeth of formulations containing no chlorine dioxide results in a failure to break down the biofilm and open up the dentinal tubules to be filled, as illustrated in relation to FIG. 7 c above.
- Application of formulations containing no hydroxyapatite (i.e. a source of both calcium and phosphate ions) and using another component instead results in the opened tubules being undesirably partially occluded, thus hindering their refilling during the remineralisation process, and thus hindering the treatment of dentine hypersensitivity.
- formulations lacking any fluoride ion source would not be able to provide any remineralisation of the tooth at all.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a multicomponent oral health care composition, comprising a source of a fluoride ion, and a source of a calcium ion, a source of a phosphate ion, and stabilised chlorine dioxide, that can be used as a toothpaste, oral spray or a mouth wash/oral rinse formulation. The different components in the composition act synergistically together to clean the teeth and mucous membranes of an oral cavity of a subject, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct unpleasant odours. They achieve this by inhibiting caries, promoting teeth remineralisation, and helping to alleviate dentine hypersensitivity, gingivitis and periodontal disease.
Description
- The present invention relates to a multicomponent oral health care composition that can be used as a toothpaste, oral spray or a mouth wash/oral rinse formulation. The different components in the composition act synergistically together to clean the teeth and mucous membranes of an oral cavity of a subject, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct unpleasant odours. They achieve this by inhibiting caries, promoting teeth remineralisation, and helping to alleviate dentine hypersensitivity, gingivitis and periodontal disease.
- Tooth mineral in humans and animals is based on calcium apatite, Ca5(PO4)3OH. Natural tooth apatites are heavily solid substituted, and the Ca2+ cations in the crystal lattice may be replaced by, for example, Sr2+, Mg2+ or Zn2+, or by two Na+ cations. The phosphate (PO4)3− anions may be replaced by carbonate ions (CO3 2−), with an associated Na+ cation replacing a Ca2+ cation or the associated loss of a hydroxyl ion (OH−). The hydroxyl ion may also be replaced by a fluoride ion (F−). This latter substitution occurs readily in tooth enamel and has several beneficial effects. In the crystal structure of calcium apatite, the hydroxyl ion is displaced slightly above the plane of a triangle of Ca(II) ions (as depicted in
FIG. 3 ), whilst the smaller fluoride ion sits in the centre of the Ca(II) triangle. This results in hydroxyapatite (HA) having a slightly distorted monoclinic crystal structure, whilst fluorapatite has a more symmetric hexagonal crystal structure. This difference leads to fluorapatite being: -
- i) More stable to acid dissolution and more resistant to the acids produced by caries forming bacteria; and
- ii) Formed more readily, since fluorapatite has a lower solubility product than hydroxyapatite.
- As a consequence of these two factors, soluble fluoride salts have been added to toothpastes, mouth rinses and drinking water for over fifty years, and fluoride has a well-documented and recognised role in anti-caries treatment. The use of fluoride as a preventive measure is well established.
- It is generally recognised that plaque that forms on teeth as a result of the activity of bacteria is not completely removed by the act of brushing teeth. The plaque may act as a reservoir for fluoride in the mouth, where it is thought to form fluorite-like species, such as calcium fluoride (CaF2). The accumulation of dental plaque biofilms, whilst it may possibly be desirable as a fluoride reservoir, is also the source of the acid-producing bacteria that cause caries and gingivitis, which can progress to become periodontal disease. Their presence is therefore undesirable. However, fluoride becomes integrated within the hydroxyapatite crystals, creating enlarged and less soluble crystals. Because these crystals are less soluble and less reactive, as they are more stable to acid dissolution and more resistant to the acids produced by caries-forming bacteria, dissolution of tooth structure by acid by-products of microorganism metabolism cannot occur as readily. The action of fluoride on hydroxyapatite crystals therefore makes it an aid in the prevention or minimisation of dental caries and periodontal disease.
- In contrast, free fluoride in saliva is rapidly diluted by salivary flow and exchange. Salivary flow rates vary enormously from individual to individual and vary during the course of the day, reducing almost to zero during sleep. Salivary flow rates are typically about 0.25 to 1.2 ml/min during the day, while the salivary volumes are typically about 1-10 ml. Additionally, salivary flow rates are observed to reduce with age and with smoking.
- Fluoride uptake into enamel, and into incipient caries lesions and the resulting formation of fluorapatite, is retarded by the presence of plaque. The plaque acts as a barrier to fluoride uptake. In the absence of plaque, fluoride uptake into enamel is extremely rapid. It is important to note that remineralisation requires a source of both Ca2+ and PO4 3− ions in addition to fluoride in order to form fluorapatite. Fluoride is proposed to enhance the precipitation of fluorapatite crystals in solutions containing calcium and phosphate and therefore tends to prevent the demineralisation of teeth. Evidence has linked fluorite to enhancing iron absorption. The calcium and phosphate may come from the saliva itself. However, particularly in individuals with low salivary flow rates, such as the elderly and smokers, or during night times when salivary flow rates are reduced, it is preferable to have an additional source of F−, Ca2+, and PO4 3− within the toothpaste itself. This may be provided by soluble forms of F−, Ca2+, and PO4 3−, or more preferably particulate, sparingly soluble forms that give rise to controlled release of calcium and phosphate as a result of the particles adhering to the teeth and gingivae and slowly dissolving. Examples include bioactive glasses, and particularly hydroxyapatite.
- Studies have demonstrated that oral gram-negative anaerobic bacteria and several species of other oral bacteria can produce volatile sulphur compounds (VSC), such as hydrogen sulphide methyl mercaptan and dimethyl sulphide. Malodorous VSC are generated primarily through the putrefactive action of oral microorganisms on sulphur-containing amino acids, peptones or proteins found in the oral cavity of a human or animal subject. These substrates are readily available in saliva and dental plaque, or may be derived from proteinaceous food particles, as well as exfoliated oral epithelium food debris.
- Stabilised chlorine dioxide (ClO2) is an aqueous solution containing chlorite ions and stabilisers. The stabilisers may comprise, for example, a carbonate or bicarbonate buffering system. When the pH of stabilised chlorine dioxide falls below a neutral pH, the molecular chlorine dioxide radical is released. The chlorine dioxide has bacteriocidal and bacteriostatic effects on the bacteria in the oral cavity of a human or animal subject. Stabilised chlorine dioxide reacts with the cell walls of microorganisms (changing the proteins and fats in the cell wall membrane), acts as a strong oxidising agent (oxidising the polysaccharide matrix that keeps the biofilm together) and effectively kills pathogenic microorganisms such as fungi, bacteria and viruses.
- Chlorine dioxide has a well proven role in destroying the bacteria involved in plaque formation, caries, gingivitis and periodontal disease, as well as eliminating halitosis. As chlorine dioxide destroys the plaque-forming bacteria, it is particularly effective in plaque removal, in conjunction with physical tooth brushing. Removal of this plaque will remove the physical barrier to fluoride, calcium and phosphate ions being able to reach the demineralised tooth surface, and thus promotes and enhances remineralisation of the tooth surface.
- However, there is always a need and a desire in the technical field to provide oral care compositions which are more effective still in effecting the minimisation of the amount of plaque within the oral cavity and facilitating the remineralisation of teeth.
- Therefore, in accordance with the present invention there is provided an oral care composition comprising:
- i) A source of a fluoride ion;
- ii) A source of a calcium ion;
- iii) A source of a phosphate ion; and
- iv) stabilised chlorine dioxide.
- These components have, to date, never been employed together in a single oral care composition. The combination of the components is surprisingly able to exhibit a synergistic effect over and above the effects observed when using each component on an individual basis, or when using a composition which does not contain all of the components.
- According to one embodiment of the invention, the source of a fluoride ion is typically a soluble fluoride salt. Exemplary sources of fluoride ions which are envisaged by the present invention include, but are not limited to, sodium fluoride, potassium fluoride, disodium monofluorophosphate, tin (II) fluoride (stannous fluoride), dipotassium fluorophosphates, calcium fluorophosphates, calcium fluoride, ammonium fluoride, aluminium fluoride, hexadecyl ammonium fluoride, 3-(N-hexadecyl-N-2-hydroxy-ethylammonio) ammonium difluoride, N,N′,N′-Tris(polyoxyethylene)-N-hexadecyl-propylenediaminedihydrofluoride disodium hexafluorosilicate, dipotassiumhexafluorosilicate, ammonium hexafluorosilicate, magnesium hexafluorosilicate, or ammonium fluorophosphates, or any combinations of two or more thereof.
- According to one embodiment, the source of fluoride ions has a concentration of fluoride between about 20 and about 1500 ppm as fluorine.
- The source of fluoride ions may have a concentration in the range of between about 0.1% to about 3.0% (w/v) in the oral care composition, typically between about 0.25% to about 2.0% (w/v), more typically between about 0.50% to about 1.5% (w/v), still more typically between about 1.00% to about 1.2% (w/v).
- According to another embodiment of the invention, both the calcium ions and the phosphate ions are typically provided by an apatite species, such as a nano-crystalline apatite. Nano-crystalline is defined herein as where the crystallites have a size of less than about 100 nm.
- In the present invention, the crystallite sizes of the apatites are determined from X-ray diffraction line width data using the Scherrer Line broadening method. In this method, the width at half height of the 002 reflection β002 is inversely proportional to crystallite length in the c-axis direction (Cullity 1956) and is given by the equation:
-
D=0.9λ/((β002 cos θ) - Where D is the crystallite size in nm; λ is the wavelength of the incident X-rays, 0.154 nm; β002 is the width at half height of the 002 reflection and cos θ is the cosine of the X-ray incident angle (25.85°). The 002 reflection is a term well known to a person skilled in the art, and is explained in, for example, the textbook ‘Elements of X-Ray Diffraction’, (3rd Edition); B. D. Cullity (2001); Addison-
Wesley Chapter 2; ISBN-10: 0201610914. - It is to be noted that this method neglects instrumental line broadening which is negligible for small nm sized crystals, and also neglects strain effects in the lattice and solid substitution effects.
- It is the unique combination of fluoride, calcium, phosphate, and stabilised chlorine dioxide, in one single oral care composition, that is able to act synergistically together to inhibit caries, promote remineralisation of the teeth, and help with dentine hypersensitivity, gingivitis and periodontal disease.
- According to one embodiment, the composition contains an appropriate buffering system. Exemplary buffer systems which are envisaged by the present invention include, but are not limited to, those comprising one or more of acetate, carbonate, citrate or phosphate salts.
- The oral care composition may be contained within, for example, a toothpaste, oral spray or a mouth wash/oral rinse formulation, or in any other formulation which may be used for the improvement of oral hygiene. Such formulations will of course be readily apparent to a person skilled in the art.
- The oral care composition of the invention is able to achieve remineralisation of incipient caries lesions much more effectively than when the components therein are utilised individually or separately. The fluoride source provides fluoride ions for forming fluorapatite, whilst the hydroxyapatite can provide both the calcium and phosphate ions, and the chlorine dioxide kills the bacteria forming the plaque. Use of this composition substantially eliminates the plaque and facilitates the uptake of Ca2+, PO4 3− and F− ions into the tooth structure and enables remineralisation to occur. The effect of the composition is further enhanced when employed in combination with physical brushing of the teeth.
- According to another embodiment, the apatite is based on the formula M5(PO4)3X, wherein M may be Ca, Sr, Zn or Mg, and X may be F, Cl or OH. Specific apatite compounds used in accordance with the invention may therefore include, but are not limited to, substituted or unsubstituted hydroxyapatites, substituted or unsubstituted fluorapatites, or substituted or unsubstituted hydroxycarbonated apatites, such as calcium hydroxyapatite, strontium hydroxyapatite, calcium hydroxycarbonated apatite, strontium hydroxycarbonated apatite, calcium fluorapatite, strontium fluorapatite, mixed strontium/calcium apatites or a mixed hydroxyfluorapatite, zinc substituted hydroxyapatite, zinc carbonated hydroxyapatite, zinc fluorapatite, or octacalcium phosphate.
- The stabilised chlorine dioxide solution may have a concentration in the range of between about 0.05% to about 2.0% (w/v) in the oral care composition, typically between about 0.075% to about 1.0% (w/v), more typically between about 0.10% to about 0.5% (w/v), still more typically between about 0.12% to about 0.2% (w/v), and/or may have a pH or be buffered to a pH of between about 6.0 and about 8.0, typically between about 7.0 and about 8.0.
- When the composition is to be used as toothpaste formulation, the source of fluoride ions may have a fluoride ion concentration of between about 300 ppm and about 1500 ppm.
- When the composition is to be used as mouth wash or oral rinse formulation, the source of fluoride ions may have an active fluoride ion concentration of between about 5 and about 500 ppm. By ‘active’ fluoride ion concentration is meant the amount of fluoride ion that is free and available for reaction and involvement in the remineralisation process. Depending upon the fluoride ion source used, this may be less than the total fluoride ion concentration in the overall oral composition.
- Also provided in accordance with the present invention is the use of a stabilised chlorine dioxide solution in combination with a source of calcium ions, a source of phosphate ions and a source of fluoride ions, to generate gaseous chlorine dioxide within the oral cavity without the use of extra oral sources of acidification. The calcium ions and phosphate ions may be provided together by an apatite species as detailed hereinabove.
- According to another embodiment, the apatite may be present in an amount of from about 0.5 to about 30 weight percent of the oral care composition. Alternatively, or in addition, the apatite may have a particle size distribution such that at least about 3% of the mass of the particles have a size less than about 5 microns and where the apatite has a crystallite size of less than about 200 nm.
- According to another embodiment of the invention, the apatite may be present in an amount of from about 0.5 to about 25 weight percent of the composition. Alternatively, or in addition, the apatite particle size distribution may have at least about 15% of the mass of the particles below about 5 microns and where the apatite crystallite size is from about 30 to about 50 nm.
- According to another embodiment, the apatite may be present from about 0.5 to about 15 weight percent of the composition. Alternatively, or in addition, at least about 50% of the mass of the particles may have a particle size less than about 5 microns.
- The composition of the invention may also contain other components selected from one or more of a solvent, a thickening agent or viscosity modifier, an abrasive, a flavour, an aromatic component, a humectant, a sweetener, a carrier, a remineralising agent, a film forming agent, a buffering agent, a cooling agent, a pH adjusting agent, an oxidizing agent, and a colorant.
- Exemplary such compounds which may be added to the composition of the invention may include, but are not limited to, glycerol, water, hydrated silica, cellulose gum, trisodium phosphate, sodium saccharin, mentha extracts, citric acid, limonene, linalool, and titanium dioxide.
- According to one embodiment of the mouth wash or oral rinse formulation of the invention, this formulation may also comprise a linear polysaccharide polymer with a high yield value that exhibits pseudoplastic flow to stabilise the HA in suspension. Typically, a linear polysaccharide gum where one or more hydroxyl groups on the monosaccharide is substituted with a functional group that comprises a carboxyl group (R—COOH), an acyl group (RCO—) or a sulphate group (R—OSO3 −) is used. Examples of such types of substituted polysaccharide include, but are not limited to, algin, xanthan gum, gellan gum and carrageenan.
- Also provided in accordance with the present invention is the use of an oral care composition in the cleaning of teeth and mucous membranes of the oral cavity of a subject, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct unpleasant odours.
- A second aspect of the invention deals with dentine hypersensitivity. Dentine hypersensitivity is felt when nerves inside the dentin of the teeth are exposed, and results in pain associated with mechanical stimuli, such as that caused by the intake of hot or cold foodstuffs into the mouth. This typically affects more than 40% of the population. It is a result of fluid flow in exposed open dentinal tubules that results in pressure changes that trigger nerve transmission within the pulp chamber of a tooth. Dentinal tubules become exposed as a result of three causes:
- i) Gingival recession where the gums recede exposing the dentine;
- ii) Loss of the enamel as a result of caries or acid erosion; or
- iii) Loss of the enamel as a result of abrasive wear accompanying tooth brushing.
- Treatment generally involves sealing or blocking the dentinal tubules. This is often achieved using specialised toothpastes that are designed to occlude the dentinal tubules. The dentinal tubule openings are typically about 2-5 microns in diameter.
- One way these tubules can be blocked is to precipitate a material onto the surface over the top of the tubules. Another approach, i.e. that used by the present invention, is to have particles comparable in size to the openings of the dentinal tubules, so the particles are able to enter into the tubules and occlude them. It is important that there are sufficient particles of the required size present to give effective numbers penetrating the dental tubules.
- Also provided in accordance with the present invention is an oral care composition as defined herein above in the remineralisation of teeth or in the treatment of dentine hypersensitivity.
- According to a further embodiment of the invention, there is provided a method of cleaning teeth and mucous membranes of the oral cavity of a subject, or perfuming them or protecting them in order to keep them in good condition, comprising applying an oral care composition as defined hereinabove.
- According to another embodiment, the apatite may be present in an amount of from about 0.5 to about 30 weight percent of the oral care composition. Alternatively, or in addition, the apatite may have a particle size distribution such that at least about 3% of the mass of the particles have a size less than about 5 microns and where the apatite has a crystallite size of less than about 200 nm.
- According to another embodiment of the invention, the apatite may be present in an amount of from about 0.5 to about 25 weight percent of the composition. Alternatively, or in addition, the apatite particle size distribution may have at least about 15% of the mass of the particles below about 5 microns and where the apatite crystallite size is from about 30 to about 50 nm.
- According to another embodiment, the apatite may be present from about 0.5 to about 15 weight percent of the composition. Alternatively, or in addition, at least about 50% of the mass of the particles may have a particle size less than about 5 microns.
- Also provided by the present invention is a toothpaste comprising an oral care composition of the invention as defined hereinabove. The apatite species in the toothpaste, such as a nano-crystalline hydroxyapatite, comprises small crystallites having a size of less than about 100 nm and a large surface area to facilitate dissolution. However, the larger particles which can occlude the dentinal tubules comprise many hundreds of crystallites aggregated together to form an approximately spherical particle with dimensions in the range 0.1 to 5 microns, and thus are similar in size to the openings to the dentinal tubules.
- Table 1 summarises the particle size data from a range of nano-crystalline hydroxyapatites in terms of the D10, D50 and D90 values which represent the volume fractions below the specified values. It can be seen from the particle sizes in the Table that they are of a similar size to the openings to the dentinal tubules, and are therefore able to occlude dentinal tubules.
-
TABLE 1 Particle Size Hydroxyapatite D10/D50/D90 Samples X-ray results FTIR (microns) A Nanocrystalline Minimal CO3 2- 1.20/4.16/11.40 Hydroxyapatite content B Nanocrystalline Minimal CO3 2- 1.19 3.78/11.15 Hydroxyapatite content C Nanocrystalline Minimal CO3 2- 0.32/2.50/22.58 Hydroxycarbonate content Broad Particle content Size D Pure Hydroxyapatite No CO3 2- 0.25/1.29/8.71 No Nanocrystallinity E Pure Hydroxyapatite Minimal CO3 2- 1.20/3.35/6.32 No Nanocrystallinity content F Nano Minimal CO3 2- 1.57/4.47/10.14 Hydroxyapatite content - All carbonate contents were <1%, and are so low they are not quantifiable. The carbonate detected is purely derived from atmospheric contamination during synthesis.
- The invention will now be described further by way of example with reference to the following Figures which are intended to be illustrative only and in no way limiting upon the scope of the invention.
-
FIG. 1 shows a scanning electron micrograph of open dentinal tubules. -
FIG. 2 shows a scanning electron micrograph of dentinal tubules being blocked by precipitate of a material over the top of the tubules. -
FIG. 3 shows a scanning electron micrograph of acid-etched dentine. -
FIG. 4 shows a scanning electron micrograph of dentinal tubules following blocking with a composition according to the invention. -
FIG. 5 shows the crystal structure of hydroxyapatite. -
FIG. 6 shows X-ray powder diffraction patterns of a nano-crystalline hydroxyapatite (nHA) and of a micro-crystalline hydroxyapatite. -
FIG. 7a shows an etched dentine surface of a mid-coronal section of a human molar. -
FIG. 7b shows a mucin-coated dentine surface to mimic biofilm. -
FIG. 7c shows a tooth surface after treatment with a chlorine dioxide toothpaste according to the invention, but containing silica powder instead of hydroxyapatite. -
FIG. 8 shows the hardness values of the tooth surface of the molars after applying a toothpaste according to the invention. -
FIG. 9 shows NMR spectra for enamel samples; non-treated, demineralised and treated with a toothpaste according to the invention. -
FIG. 10 shows NMR spectra for enamel samples non-treated, demineralised and treated with a mouth wash according to the invention. -
FIG. 11 shows a graph illustrating the amount of total fluoride in a mouth wash according to the invention in relation to the amount of active, or free, fluoride available for remineralisation. -
FIG. 12 shows a graph illustrating the enamel weight loss during the demineralisation and treatment with a toothpaste according to the invention. -
FIG. 13 shows a scanning electron micrograph of a dentine surface of a specimen treated for 1 day with a mouth wash according to the invention (4×2 minutes of treatment, followed by remineralisation). -
FIG. 14 shows a graph illustrating reduction in fluid flow through dentinal tubules following tooth brushing with a toothpaste according to the invention. -
FIG. 1 shows a scanning electron micrograph of open dentinal tubules. One way these tubules can be blocked is to precipitate a material onto the surface over the top of the tubules. This is shown inFIG. 2 , which depicts a material (in this instance, Colgate ProRelief) over the top of the tubules. As can be seen, not many of the openings of the tubules are blocked. -
FIG. 3 shows a scanning electron micrograph of acid etched dentine, i.e. a molar tooth cut through the mid coronal section, which has been acid etched using 6% citric acid for 2 minutes. The tubules are clearly visible. The scanning electron micrograph inFIG. 4 shows these same tubules after a composition according to the invention comprising 7.5 wt % hydroxyapatite has been applied to the tooth. It can be seen that the dentinal tubules are substantially blocked by the particles in the composition, thus preventing the fluid flow through the dentinal tubules and minimising pain for the subject. - In
FIG. 5 , the crystal structure of hydroxyapatite, it can be seen that the smaller fluoride ion sits in the centre of the Ca(II) triangle, while the hydroxyl ion is displaced slightly above the plane of the triangle of Ca(II) ions. - In
FIG. 6 , there is a comparison between the X-ray powder diffraction patterns of a nano-crystalline hydroxyapatite (nHA) and of a larger microcrystalline hydroxyapatite. It can be seen that the diffraction pattern of the nHA shows pronounced line broadening compared with that of the microcrystalline hydroxyapatite. Using Sherrer line broadening analysis, the nHCA has a crystallite size of 30 to 50 nm. - The method of manufacture of a typical toothpaste formulation according to the invention may be carried out in accordance with the following procedure:
- To a vessel, purified water BP is added and stirring commences. Sodium saccharin, trisodium phosphate and sodium monofluorophosphate are added and allowed to dissolve. Glycerin and cellulose gum are premixed thoroughly and added to the main vessel using high shear mixing. Hydrated silica, hydroxyapatite and titanium dioxide are added and mixed under high shear until a smooth homogenous paste is created. The vessel has a jacket which is cooled with chilled water to ensure the contents remain below 40° C.
- Menthol, peppermint oil BP & spearmint oil BP are premixed in a separate vessel to create the flavour blend. This is subsequently added to the paste in the main vessel with mixing.
-
Chlorine dioxide 5% solution (proprietary blend) is added to the paste with mixing, and the pH of the paste is adjusted to comply with the specification using a citric acid/purified water BP premix and adequate stirring. - The final toothpaste formulation contains 1250 ppm of chlorine dioxide, 10900 ppm of sodium monofluorophosphate (which equates to 1428 ppm of fluoride in the monofluorophosphate, calculated by using the respective atomic and molecular weights of fluorine and sodium monofluorophosphate, which are 19 and 145, respectively), and 75000 ppm of hydroxyapatite.
- The method of manufacture of a typical oral rinse or mouth wash formulation according to the invention may be carried out in accordance with the following procedure:
- To a vessel, purified water BP/EP is added and is heated to 80° C. (±5° C.,). The water is then stirred and recirculated through an in-line high shear homogeniser.
- Kelcogel HA (high acyl content gellan gum a polysaccharide consisting of glucose, rhamnose, and glucuronic acid repeat units and with a substituent glycerate moiety on every glucose unit and an acetate moiety on every second glucose moiety) and Cekol 4000 (a carboxymethyl cellulose polymer, used to minimise flocculation and aid bioadhesion) are pre-mixed in glycerol to wet-out. The glycerol containing the pre-mix is then added to the hot water. The resultant mixture is stirred and homogenised for 15 minutes before cooling.
- When the temperature of the water reaches ≦65° C., sodium monofluorophosphate is then added to the vessel, followed by sodium citrate, trisodium citrate and sodium saccharin. The introduction of Na+ ions to the mixture causes the high acyl content gellan gum to thicken and form a fluid, highly mobile gel. The mixing and homogenising is continued.
- When the temperature of the mixture in the vessel reaches ≦55° C., hydroxyapatite is added. The stirring and homogenising is continued until the mixture is fully dispersed and free from lumps. The homogeniser is then turned off and the mixture is stirred as it cools further.
- In a separate vessel, a flavour pre-mix is prepared by adding
polysorbate 20, PEG-60 hydrogenated castor oil, Frescolat MGA and Coolmint FL72627. These components are mixed thoroughly until a clear solution is obtained. - When the temperature of the mixture in the vessel reaches ≦40° C., sodium benzoate is added, and is allowed to fully dissolve with mixing. The flavour pre-mix is then also added to the main vessel, and the mixing continues.
- When the temperature of the mixture in the vessel reaches ≦35° C., chlorine dioxide solution is added. The homogeniser is turned back on and the mixture is allowed to mix and homogenise for at least 15 minutes.
- Citric acid is then added, and the mixture is allowed to mix for a further 15 minutes, to ensure that the pH of the product is 8.0-8.5. The homogenising and stirring then ceases, and the resultant product is protected from exposure to sunlight.
- The final mouth wash or oral rinse formulation contains 1250 ppm of chlorine dioxide, 5000 ppm of sodium monofluorophosphate (which equates to 655 ppm of fluoride in the monofluorophosphate, again calculated by using the respective atomic and molecular weights of fluorine and sodium monofluorophosphate), and 50000 ppm of hydroxyapatite.
- One of the key aspects of the present invention is the use of chlorine dioxide combined with the use of an apatite and fluoride. The chlorine dioxide role in the formulation is to remove plaque and biofilm from the tooth surface and particularly from exposed dentine surfaces; this serves to open the dentinal tubules and facilitates the subsequent occlusion of the dentinal tubules by the apatite particles. Conventionally, in laboratory studies of dentinal tubule, occlusion of mid coronal sections of human molars this is achieved using 6% citric acid or 35% orthophosphoric acid. Chlorine dioxide fulfils the same purpose within the toothpaste or oral rinse.
-
FIG. 7a shows an SEM of a mid-coronal section of a human molar treated with 6% citric acid for 2 minutes to open the dentinal tubules then painted with a 2.5% solution of mucin, a common salivary protein, air dried and then followed by a stabilisation treatment with 10% formalin solution. The process was repeated to produce a water stable protein biofilm. It can be seen (FIG. 7b ) that following treatment the tubules are occluded with the biofilm. A toothpaste where the occluding agent in the formulation, hydroxyapatite, is replaced by silica powder was then applied to the tooth surface for 2 minutes, followed by rinsing with distilled water. It can be seen (FIG. 7c ) that the chlorine dioxide in the toothpaste breaks down the protein layer and opens the dentinal tubules. However, it must also be noted that the silica added to replace the hydroxyapatite in the toothpaste acts in a negative manner to partially occlude some of the dentinal tubules. Application of formulations without the chlorine dioxide failed to result in opening of the dentinal tubules. - One of the key aspects of the invention is the ability of the apatite to work in conjunction with a source of fluoride to promote remineralisation. This is particularly important with regard to replacing lost tooth mineral due to acid erosion, incipient caries, or to promote the conversion of the apatite occluding the dentinal tubules to more durable fluoridated apatite. This is illustrated by two techniques:
-
- i) Surface micro-hardness measurements, since an increase in mineral content results in an increase in hardness; or
- ii) Direct evidence of the formation of the formation of fluoridated apatite using 19F solid state nuclear magnetic resonance spectroscopy using enamel slices and associated weight changes and fluoride measurements.
- Studies were carried out according to the following experiment protocol. Fifteen human molars were collected, disinfected, embedded in resin, polished down to reveal longitudinal section and finished with 1 micron diamond paste. Enamel hardness was evaluated using a microhardness tester (Duramin-1/-2; Struers, Copenhagen, Denmark) with a Vicker's indenter (a square pyramid diamond shape indenter) under a load of 50 g for 15 seconds. 10 indentations per sample were taken. The two diagonal indentation lengths were measured and then used for microhardness calculation using the following equation:
-
- where F is in kilogram-force (kgf), A is the area of the point of the indenter, and d is the average length of the diagonal left by the indenter in millimeters.
- The teeth specimens were demineralised in a demineralisation solution (pH=4.5, 50 mM acetic acid to mimic an acidic challenge during a caries attack) and the hardness was then again measured.
- The toothpaste of the invention was then applied to the tooth surface and the hardness again measured.
FIG. 8 shows the hardness values. Following the acid challenge the hardness decreases significantly, but increases significantly after exposure to the toothpaste providing clear evidence of remineralisation. - Caries-free first molar and premolars were collected and stored in 3% sodium hypochlorite solution for 24 hours. Teeth were mounted in acrylic resin, and sliced using an annular diamond blade (
Microslice 2, Malvern Instrument, UK) to get enamel sections (approximately 6×5×1 mm3). Excess dentine area was removed by polishing against P600 silicon carbide paper. - The enamel blocks were then rinsed off with de-ionized water, dried in air for 30 minutes and weighed using a digital microbalance. Each enamel section was immersed in 50 ml acetic acid solution (0.1 M, pH=4.0) and agitated at a rate of 60 rpm in a 37° C. incubator (KS 4000 I control, IKA) for 24 hours. The enamel specimens were then immersed in the toothpaste according to the invention, Ultradex Toothpaste (diluted 1:10 with acetic acid solution (pH=4.0) to give a 0.1M final solution, to mimic the real mouth situation), or in the mouth wash according to the invention, Ultradex Recalcifying and Whitening Oral Rinse treatment solution (diluted 1:2 both with 0.2 M acetic acid solution (pH=4.0) to mimic the real mouth situation), placed back in the incubator, and agitated at a rate of 60 rpm for 96 hours. After treatment, the enamel blocks were cleaned, dried and weighed. The enamel weight loss was presented in percentages. Enamel samples (no treatment, 24 hours demineralised and demineralization followed by the treatments) were ground to powder using a vibratory mill (MM200, Glen Creston Ltd, UK) with a 25 ml zirconia grinding jar for 15 seconds under 20 Hz. The powder was then used for solid-state NMR experiments using the 600 MHz (14.1 T) Bruker spectrometer. The 19F solid state NMR measurements were run at the resonance frequency of 564.7 MHz with a 2.5 mm rotor spun at 18 and 21 kHz. Spectra were obtained by overnight scans with 8 preliminary dummy scans and 60 seconds recycling delay. The chemical shift was referenced using the signal from the 1M NaF solution scaled to −120 ppm relative to the CF3Cl primary standard.
- The NMR spectra showed flat lines for both the non-treated enamel sample and the demineralised enamel sample (
FIGS. 9 and 10 ). Therefore, there was no fluoride detected for both samples. This indicated that no significant fluoride was present in the original tooth samples. The spectra were then run for the toothpaste and oral rinse samples. The toothpaste with both HA and monofluorophosphate (MFP) showed the presence of fluorapatite with a chemical shift of −103 ppm, the position being almost identical to the chemical shift of the fluorine in fluorapatite (−102 ppm), as did the toothpaste with MFP alone treated samples. The HA toothpaste alone gave a very small signal close to that of fluorite, which was probably present in the original tooth. The oral rinse treated enamel sample showed a broad peak centered at around −103 ppm, This demonstrates that after demineralisation treatment, the Ultradex Recalcifying and Whitening Toothpaste and Oral Rinse treatment of the invention led to fluorapatite formation. The reference spectrum for the fluorapatite was based on synthetic pure fluorapatite, which demonstrates a distinct sharp peak with a chemical shift at −102 ppm. The apatite that comprises the tooth enamel is a solid solution formed rather than stoichiometric. It could contain different ions such as Magnesium (Mg2+) and Manganese (Mn2+) substituted for Ca2+, fluoride (F−) substituted for hydroxyl (OH−), and carbonate (CO3 2−) substituted for phosphate (PO4 3−). The crystal structure is therefore distorted. With demineralisation and subsequent remineralisation, the fluorapatite crystals formed could therefore be slightly disordered. This may explain why the spectrum for the Ultradex Recalcifying and Whitening Toothpaste and Oral Rinse of the invention treated enamel showed broader peaks when compared with the fluorapatite reference. Fluoride promotes remineralisation and the fluorapatite formed is more acid resistant compared with the hydroxyapatite and carbonated hydroxyapatite. However, high concentrations of fluoride with insufficient phosphate ions may result in the formation of the undesirable calcium fluoride phase. - An Ultradex Recalcifying and Whitening Oral Rinse/mouth wash of the invention contains 660 ppm F− in the form of monofluorophosphate, with a 1:2 dilution, the total available F− was 330 ppm. However, the actual available F− detected by a fluoride selective electrode (ORION 9609BN PH/ISE meter model 710 A, USA) (
FIG. 11 ) was only 24.5 ppm. The F− after the remineralisation was 19.5 and this gave an F− loss of 5 ppm. This further confirms fluoride is being incorporated into the apatite. - The weight loss of the sample toothpaste specimens are given in
FIG. 12 . Both MFP and HA acted to reduce weight loss and enamel demineralisation. However the biggest reduction in weight loss was found for the Ultradex Recalcifying and Whitening Oral Toothpaste treatment. This indicates that the fluoride acts synergistically with the HA to inhibit demineralisation and promote remineralisation. - Further, the scanning electron micrograph in
FIG. 13 clearly demonstrates that a tooth specimen that is treated over a period using the mouth wash of the invention—in this case over 1 day, with 4 lots of 2 minutes' worth of treatment with the mouth wash, followed by the remineralisation—achieves the aim of successfully occluding the dentinal tubules, and thus reduce dentine hypersensitivity. - In
FIG. 14 , it can be seen from the graph that there is a reduction in fluid flow through dentinal tubules following tooth brushing with a toothpaste according to the invention, thus indicating that the tubules have been successfully blocked by the action of the fluoride in the remineralisation process. This is a test that is routinely used as a measure of the efficacy of a hypersensitivity toothpaste. - Therefore, in summary, it can be seen that the composition of the invention provides technical advantages over existing formulations lacking any one of the defined components. Application to the surface of teeth of formulations containing no chlorine dioxide results in a failure to break down the biofilm and open up the dentinal tubules to be filled, as illustrated in relation to
FIG. 7c above. Application of formulations containing no hydroxyapatite (i.e. a source of both calcium and phosphate ions) and using another component instead results in the opened tubules being undesirably partially occluded, thus hindering their refilling during the remineralisation process, and thus hindering the treatment of dentine hypersensitivity. Finally, it is clear that formulations lacking any fluoride ion source would not be able to provide any remineralisation of the tooth at all. - It is of course to be understood that the present invention is not intended to be restricted to the foregoing examples which are described by way of example only.
Claims (21)
1. An oral care composition comprising:
i) A source of a fluoride ion;
ii) A source of a calcium ion;
iii) A source of a phosphate ion; and
iv) stabilised chlorine dioxide.
2. An oral care composition according to claim 1 , wherein the source of a calcium ion and the source of a phosphate ion is an apatite species.
3. An oral care composition according to claim 2 , wherein the apatite species is based on the formula M5(PO4)3X, wherein M is Ca, Sr, Zn or Mg, and X is F, Cl or OH.
4. An oral care composition according to claim 2 , wherein the apatite species is a substituted or unsubstituted hydroxyapatite or a substituted or unsubstituted fluorapatite.
5. An oral care composition according to claim 2 , wherein the apatite species is selected from calcium hydroxyapatite, strontium hydroxyapatite, calcium hydroxycarbonated apatite, strontium hydroxycarbonated apatite, calcium fluorapatite, strontium fluorapatite, mixed strontium calcium apatites or a mixed hydroxyfluorapatite, zinc substituted hydroxyapatite, zinc carbonated hydroxyapatite, zinc fluorapatite, octacalcium phosphate, or a mixture of any two or more thereof.
6. An oral care composition according to claim 2 , wherein the apatite is present in an amount of from about 0.5 to about 30 weight percent of the composition, and/or the apatite has a particle size distribution, where at least about 3% of the mass of the particles have a size less than about 5 microns and where the apatite has a crystallite size of less than about 200 nm, as determined using Scherrer Line broadening.
7. An oral care composition according to claim 1 , wherein the source of fluoride ion is selected from sodium fluoride, potassium fluoride, disodium monofluorophosphate, tin(II)fluoride, dipotassium fluorophosphates, calcium fluorophosphates, calcium fluoride, ammonium fluoride, aluminium fluoride, hexadecyl ammonium fluoride, 3-(N-hexadecyl-N-2-hydroxy-ethylammonio) ammonium difluoride, N,N′,N′-Tris(polyoxyethylene)-N-hexadecyl-propylenediaminedihydrofluoride disodium hexafluorosilicate, dipotassiumhexafluorosilicate, ammonium hexafluorosilicate, magnesium hexafluorosilicate or ammonium fluorophosphates, or any combinations of two or more thereof.
8. An oral care composition according to claim 1 , wherein the source of fluoride ion has a concentration between 20 and 1500 ppm as fluorine.
9. An oral care composition according to claim 8 , wherein when the composition is to be used as toothpaste, the fluoride concentration is between 300 and 1500 ppm.
10. An oral care composition according to claim 8 , wherein when the composition is to be used as mouth wash, the active fluoride concentration is between 5 and 500 ppm.
11. An oral care composition according to claim 1 , further comprising a buffer system.
12. An oral care composition according to claim 11 , wherein the buffer system comprises one or more selected from acetate, carbonate, citrate or phosphate-containing species.
13. An oral care composition according to claim 1 , wherein the pH of the composition is between about 6.0 and about 8.0.
14. An oral care composition according to claim 1 , wherein when the composition is a mouth wash or oral rinse, it further comprises a linear polysaccharide polymer.
15. An oral care composition according to claim 14 , wherein the linear polysaccharide polymer is a linear polysaccharide gum, wherein one or more hydroxyl groups on the monosaccharide is substituted with a functional group comprising a group selected from a carboxyl group (R—COOH), an acyl group (RCO—) or a sulphate group (R—OSO3 −).
16. An oral care composition according to claim 1 in the remineralisation of teeth or in the treatment of dentine hypersensitivity.
17. A toothpaste, oral spray, mouthwash or oral rinse formulation comprising an oral care composition according to claim 1 .
18. (canceled)
19. (canceled)
20. (canceled)
21. A method of cleaning teeth and mucous membranes of the oral cavity of a subject, or perfuming them or protecting them in order to keep them in good condition, comprising applying an oral care composition according to claim 1 .
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/229,757 US20170182092A1 (en) | 2012-02-10 | 2016-08-05 | Multicomponent oral care composition |
US15/857,973 US20180325942A1 (en) | 2012-02-10 | 2017-12-29 | Multicomponent oral care composition |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1202341.2A GB201202341D0 (en) | 2012-02-10 | 2012-02-10 | Multicomponent oral care compostion |
GB1202341.2 | 2012-02-10 | ||
PCT/GB2013/050250 WO2013117913A2 (en) | 2012-02-10 | 2013-02-04 | Multicomponent oral care composition |
US201414378045A | 2014-08-11 | 2014-08-11 | |
US14/959,700 US9408788B2 (en) | 2012-02-10 | 2015-12-04 | Multicomponent oral care composition |
US15/229,757 US20170182092A1 (en) | 2012-02-10 | 2016-08-05 | Multicomponent oral care composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/959,700 Continuation US9408788B2 (en) | 2012-02-10 | 2015-12-04 | Multicomponent oral care composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/857,973 Continuation US20180325942A1 (en) | 2012-02-10 | 2017-12-29 | Multicomponent oral care composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170182092A1 true US20170182092A1 (en) | 2017-06-29 |
Family
ID=45929942
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/378,045 Expired - Fee Related US9211240B2 (en) | 2012-02-10 | 2013-02-04 | Multicomponent oral care composition |
US14/959,700 Expired - Fee Related US9408788B2 (en) | 2012-02-10 | 2015-12-04 | Multicomponent oral care composition |
US15/229,757 Abandoned US20170182092A1 (en) | 2012-02-10 | 2016-08-05 | Multicomponent oral care composition |
US15/857,973 Abandoned US20180325942A1 (en) | 2012-02-10 | 2017-12-29 | Multicomponent oral care composition |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/378,045 Expired - Fee Related US9211240B2 (en) | 2012-02-10 | 2013-02-04 | Multicomponent oral care composition |
US14/959,700 Expired - Fee Related US9408788B2 (en) | 2012-02-10 | 2015-12-04 | Multicomponent oral care composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/857,973 Abandoned US20180325942A1 (en) | 2012-02-10 | 2017-12-29 | Multicomponent oral care composition |
Country Status (18)
Country | Link |
---|---|
US (4) | US9211240B2 (en) |
EP (2) | EP2812010B1 (en) |
JP (1) | JP6101712B2 (en) |
KR (1) | KR20140143757A (en) |
CN (1) | CN104254336A (en) |
AU (1) | AU2013217399B2 (en) |
BR (1) | BR112014019654B1 (en) |
CA (1) | CA2863674C (en) |
DK (1) | DK2812010T3 (en) |
ES (2) | ES2862431T3 (en) |
GB (2) | GB201202341D0 (en) |
MX (1) | MX343104B (en) |
NZ (1) | NZ628772A (en) |
PL (2) | PL3207934T3 (en) |
PT (2) | PT2812010T (en) |
RU (1) | RU2014136229A (en) |
WO (1) | WO2013117913A2 (en) |
ZA (1) | ZA201406491B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
US20110318282A1 (en) * | 2008-12-22 | 2011-12-29 | Micropure, Inc. | Composition and method for reducing demineralization of teeth |
US20100233101A1 (en) | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
US10695370B2 (en) | 2013-07-23 | 2020-06-30 | The University Of Melbourne | Compositions and methods for dental mineralization |
MX2016008482A (en) | 2013-12-24 | 2016-10-26 | Univ Melbourne | Stabilized stannous compositions. |
RU2720242C2 (en) * | 2014-12-24 | 2020-04-28 | Юниверсити Оф Мельбурн | Mineralizing fluorine-containing compositions |
CN106619157A (en) * | 2017-01-15 | 2017-05-10 | 南通上水电子科技有限公司 | Anti-caries anti-allergic purified water and preparing method thereof |
PL3595615T3 (en) | 2017-03-14 | 2024-05-13 | The University Of Melbourne | Treatment for gingivitis |
CA3020197C (en) | 2017-09-01 | 2024-06-04 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
EP3904281A4 (en) * | 2018-12-27 | 2022-09-21 | Shiraishi Kogyo Kaisha, Ltd. | Hydroxyapatite particulate |
JP2021008415A (en) * | 2019-06-28 | 2021-01-28 | サンスター スイス エスエー | Composition for oral cavity |
WO2020138500A1 (en) | 2018-12-27 | 2020-07-02 | サンスター スイス エスエー | Composition for oral cavity |
JP2020105106A (en) * | 2018-12-27 | 2020-07-09 | サンスター スイス エスエー | Oral composition |
JP2021008417A (en) * | 2019-06-28 | 2021-01-28 | サンスター スイス エスエー | Composition for oral cavity |
JP2021008416A (en) * | 2019-06-28 | 2021-01-28 | サンスター スイス エスエー | Composition for oral cavity |
JP2021008418A (en) * | 2019-06-28 | 2021-01-28 | サンスター スイス エスエー | Composition for oral cavity |
JP7341749B2 (en) * | 2019-06-28 | 2023-09-11 | サンスター株式会社 | Oral composition |
JP7346102B2 (en) * | 2019-06-28 | 2023-09-19 | サンスター株式会社 | Oral composition |
JP2021008424A (en) * | 2019-06-28 | 2021-01-28 | サンスター株式会社 | Composition for oral cavity |
JP7341748B2 (en) * | 2019-06-28 | 2023-09-11 | サンスター株式会社 | Oral composition |
JP2021008428A (en) * | 2019-06-28 | 2021-01-28 | サンスター株式会社 | Oral composition |
JP7358088B2 (en) * | 2019-06-28 | 2023-10-10 | サンスター株式会社 | Oral composition |
JP7341751B2 (en) * | 2019-06-28 | 2023-09-11 | サンスター株式会社 | Oral composition |
JP7465658B2 (en) * | 2019-12-27 | 2024-04-11 | サンスター株式会社 | Oral Composition |
JP7562255B2 (en) * | 2019-12-27 | 2024-10-07 | サンスター株式会社 | Oral Composition |
JP2023510195A (en) | 2020-01-03 | 2023-03-13 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Topically administered TNAP to promote periodontal health |
GB202020423D0 (en) | 2020-12-22 | 2021-02-03 | Univ London Queen Mary | Composition comprising calcium phosphate and a bioactive glass comprising fluorine |
CN114014288B (en) * | 2021-11-09 | 2022-12-13 | 中南大学 | Calcium fluoride modified hydroxyapatite powder and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902498A (en) * | 1988-06-01 | 1990-02-20 | The Procter & Gamble Company | Oral compositions |
US5302373A (en) * | 1993-06-10 | 1994-04-12 | Church & Dwight Co., Inc. | Liquid mouthwash containing a particulate bicarbonate suspension |
US20090175917A1 (en) * | 2006-04-13 | 2009-07-09 | S&C Polymer, Silicon- Und Composite Spezialitaten Gmbh | Tooth Bleaching Agent |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH578351A5 (en) | 1971-07-13 | 1976-08-13 | Scheller Durodont Dr | |
US4348381A (en) * | 1981-05-06 | 1982-09-07 | Colgate-Palmolive Company | Dental remineralization composition |
US4566636A (en) | 1983-07-11 | 1986-01-28 | Micropure, Incorporated | Producing liquid droplets bearing electrical charges |
US4545525A (en) | 1983-07-11 | 1985-10-08 | Micropure, Incorporated | Producing liquid droplets bearing electrical charges |
US4855135A (en) | 1984-07-30 | 1989-08-08 | Ratcliff Perry A | Method for debriding |
US4837009A (en) | 1986-03-31 | 1989-06-06 | Ratcliff Perry A | Method and composition for prevention of plaque formation and plaque dependent diseases |
US4886657A (en) | 1984-07-30 | 1989-12-12 | Ratcliff Perry A | Method for preventing periodontitis |
US4818519A (en) * | 1986-12-29 | 1989-04-04 | Ratcliff Perry A | Method and composition for prevention of plaque formation and plaque dependent diseases |
US4689215A (en) | 1984-07-30 | 1987-08-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4889714A (en) | 1984-07-30 | 1989-12-26 | Ratcliff Perry A | Method for retarding dental plaque by killing streptococcus sanguis |
US4696811A (en) | 1984-07-30 | 1987-09-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4975285A (en) | 1984-07-30 | 1990-12-04 | Ratcliff Perry A | Method for cleaning dental prosthetic devices |
US4788053A (en) | 1984-07-30 | 1988-11-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4793989A (en) | 1984-07-30 | 1988-12-27 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
AU4953585A (en) | 1985-10-01 | 1987-04-24 | Micropure, Inc. | Producing liquid droplets bearing electrical charges |
JPS63501692A (en) | 1985-10-01 | 1988-07-14 | マイクロピュア−・インコ−ポレ−テッド | Formation of charged droplets |
IT1208577B (en) | 1985-10-07 | 1989-07-10 | Micropure Inc | Electrically charged liquid droplets production appts. |
AU642128B2 (en) | 1986-03-31 | 1993-10-14 | Micropure, Inc. | Improved method and composition for prevention of plaque formation and plaque dependent diseases |
US4792442A (en) | 1986-03-31 | 1988-12-20 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4925656A (en) | 1986-03-31 | 1990-05-15 | Ratcliff Perry A | Method for retarding formation of dental plaque |
US4786492A (en) | 1986-03-31 | 1988-11-22 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4851213A (en) | 1986-03-31 | 1989-07-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease due to S. Sanguis |
US5348734A (en) | 1990-11-20 | 1994-09-20 | Micropure Inc. | Oral health preparation and method |
EP0613678B1 (en) | 1986-12-29 | 1997-11-19 | Micropure, Inc. | Oral care composition |
US5200171A (en) | 1990-11-20 | 1993-04-06 | Micropure, Inc. | Oral health preparation and method |
US4808389A (en) | 1986-12-29 | 1989-02-28 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
GB8811828D0 (en) * | 1988-05-19 | 1988-06-22 | Unilever Plc | Oral compositions |
GB8927073D0 (en) | 1989-11-30 | 1990-01-31 | Unilever Plc | Oral compositions |
US5052590A (en) | 1990-05-09 | 1991-10-01 | Ratcliff Perry A | Resealable dual compartment container |
US5112479A (en) | 1990-05-30 | 1992-05-12 | Micropure Filtration, Inc. | Oil purification unit with cyclonic reservoir section and filtration section |
ATE160286T1 (en) | 1993-03-02 | 1997-12-15 | Micropure Inc | ORAL CARE PRODUCTS |
US5489435A (en) | 1993-07-06 | 1996-02-06 | Ratcliff; Perry A. | Composition for treatment of abnormal conditions of the epithelium of bodily orifices |
US6200557B1 (en) | 1993-07-06 | 2001-03-13 | Perry A. Ratcliff | Method of treating HIV by a topical composition |
US6136348A (en) | 1997-12-05 | 2000-10-24 | Ratcliff; Perry A. | Compound and method for degrading amino acids |
US6114398A (en) | 1998-03-03 | 2000-09-05 | Ratcliff; Perry A. | Personal lubricant to prevent and stop itching |
IT1299563B1 (en) * | 1998-07-17 | 2000-03-16 | Giovanni Dolci | ODONTOSTOMATOLOGICAL USE OF NANOSTRUCTURED APATITIC BASED MATERIALS |
US6277363B1 (en) | 1998-09-21 | 2001-08-21 | Vortech, Inc. | Method and composition for treating chlamydia infection |
US6208881B1 (en) | 1998-10-20 | 2001-03-27 | Micropure Medical, Inc. | Catheter with thin film electrodes and method for making same |
US6030391A (en) | 1998-10-26 | 2000-02-29 | Micropure Medical, Inc. | Alignment gauge for metatarsophalangeal fusion surgery |
DE19946645B4 (en) | 1999-09-29 | 2012-01-26 | Protec Carrier Systems Gmbh | Method for detaching a film system from an electrostatic holding system |
JP3971881B2 (en) * | 2000-02-01 | 2007-09-05 | 株式会社サンギ | Oral composition |
US6582682B2 (en) | 2000-10-30 | 2003-06-24 | Noville, Inc. | Oral care compositions comprising stabilized chlorine dioxide |
US20030003059A1 (en) * | 2001-04-03 | 2003-01-02 | Frederic Dana | Dentifrice compositions |
US6878373B2 (en) | 2001-12-03 | 2005-04-12 | Micropure Technologies, Inc. | Probiotic composition containing Bacillus cereus RRRL B-30535 |
WO2005097053A1 (en) | 2004-04-01 | 2005-10-20 | Smithkline Beecham Corporation | Dissolvable tooth whitening strip |
DE102004025030A1 (en) | 2004-05-18 | 2005-12-15 | S&C Polymer Silicon- und Composite-Spezialitäten GmbH | Nano-apatite fillers containing curable restorative materials |
CA2474113A1 (en) * | 2004-07-26 | 2006-01-26 | Jose Y. Ibusca | All-in-one toothbrush, toothpaste, plaque & tartar remover |
US20060134020A1 (en) * | 2004-12-21 | 2006-06-22 | Robinson Richard S | Anti-caries oral care composition with a chelating agent |
EP1885325A1 (en) * | 2005-04-11 | 2008-02-13 | Remedent NV | Foam strip for the delivery of oral care compositions |
US20060292092A1 (en) * | 2005-06-22 | 2006-12-28 | Deepak Sharma | Oral care compositions, devices, and methods of using the same |
GB0524803D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Novel compositions |
WO2007066837A1 (en) * | 2005-12-06 | 2007-06-14 | Lg Household & Health Care Ltd. | Delivery system for tooth whitening component using in situ gelling |
NZ569785A (en) * | 2006-02-09 | 2011-07-29 | Univ Melbourne | Fluoride composition comprising phosphopeptide-stabilized amorphous calcium phosphate (ACP) and methods for dental mineralization |
WO2008147997A1 (en) | 2007-05-24 | 2008-12-04 | Ada Foundation | Tooth fluoridating and remineralizing compositions and methods, based on nanoaggregate formation |
US8926951B2 (en) | 2007-07-09 | 2015-01-06 | Micropure, Inc. | Composition for preventing oral disease by penetrating polymicrobial oral biofilms and killing oral pathogens |
US7875460B2 (en) | 2007-07-09 | 2011-01-25 | Micropure, Inc. | Method for determining the effectiveness of stabilized chlorine dioxide in a mouth rinse |
US20090016973A1 (en) | 2007-07-09 | 2009-01-15 | Micropure, Inc. | Composition and Method for the Prevention of Oral Disease |
US20090317339A1 (en) * | 2008-06-23 | 2009-12-24 | Deepak Sharma | Teeth Bleaching Compositions and Devices |
US8697141B2 (en) | 2008-08-26 | 2014-04-15 | Micropure, Inc. | Method and composition for preventing and healing osteonecrosis of the jaw |
US20110318282A1 (en) * | 2008-12-22 | 2011-12-29 | Micropure, Inc. | Composition and method for reducing demineralization of teeth |
US20100233101A1 (en) | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
WO2011094872A1 (en) * | 2010-02-03 | 2011-08-11 | Swissdent Cosmetics Ag | Oral care composition comprising a precursor of chlorine dioxide and lipophilic excipients |
US20120164084A1 (en) | 2010-12-22 | 2012-06-28 | Micropure, Inc. | Composition and method to flavor oral care compositions containing a chlorine dioxide source |
-
2012
- 2012-02-10 GB GBGB1202341.2A patent/GB201202341D0/en not_active Ceased
-
2013
- 2013-02-01 GB GB1301794.2A patent/GB2499317B/en not_active Expired - Fee Related
- 2013-02-04 KR KR1020147025290A patent/KR20140143757A/en not_active Application Discontinuation
- 2013-02-04 PT PT137082202T patent/PT2812010T/en unknown
- 2013-02-04 RU RU2014136229A patent/RU2014136229A/en not_active Application Discontinuation
- 2013-02-04 NZ NZ628772A patent/NZ628772A/en not_active IP Right Cessation
- 2013-02-04 PT PT171652605T patent/PT3207934T/en unknown
- 2013-02-04 CN CN201380019125.2A patent/CN104254336A/en active Pending
- 2013-02-04 PL PL17165260T patent/PL3207934T3/en unknown
- 2013-02-04 PL PL13708220T patent/PL2812010T3/en unknown
- 2013-02-04 WO PCT/GB2013/050250 patent/WO2013117913A2/en active Application Filing
- 2013-02-04 US US14/378,045 patent/US9211240B2/en not_active Expired - Fee Related
- 2013-02-04 BR BR112014019654-0A patent/BR112014019654B1/en not_active IP Right Cessation
- 2013-02-04 JP JP2014556137A patent/JP6101712B2/en not_active Expired - Fee Related
- 2013-02-04 DK DK13708220.2T patent/DK2812010T3/en active
- 2013-02-04 ES ES17165260T patent/ES2862431T3/en active Active
- 2013-02-04 EP EP13708220.2A patent/EP2812010B1/en active Active
- 2013-02-04 AU AU2013217399A patent/AU2013217399B2/en not_active Ceased
- 2013-02-04 ES ES13708220.2T patent/ES2644050T3/en active Active
- 2013-02-04 CA CA2863674A patent/CA2863674C/en not_active Expired - Fee Related
- 2013-02-04 EP EP17165260.5A patent/EP3207934B1/en active Active
- 2013-02-04 MX MX2014009572A patent/MX343104B/en active IP Right Grant
-
2014
- 2014-09-04 ZA ZA2014/06491A patent/ZA201406491B/en unknown
-
2015
- 2015-12-04 US US14/959,700 patent/US9408788B2/en not_active Expired - Fee Related
-
2016
- 2016-08-05 US US15/229,757 patent/US20170182092A1/en not_active Abandoned
-
2017
- 2017-12-29 US US15/857,973 patent/US20180325942A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902498A (en) * | 1988-06-01 | 1990-02-20 | The Procter & Gamble Company | Oral compositions |
US5302373A (en) * | 1993-06-10 | 1994-04-12 | Church & Dwight Co., Inc. | Liquid mouthwash containing a particulate bicarbonate suspension |
US20090175917A1 (en) * | 2006-04-13 | 2009-07-09 | S&C Polymer, Silicon- Und Composite Spezialitaten Gmbh | Tooth Bleaching Agent |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9408788B2 (en) | Multicomponent oral care composition | |
Enax et al. | Synthetic hydroxyapatite as a biomimetic oral care agent. | |
EP2089040B1 (en) | Oral care product | |
TWI513469B (en) | Oral care products comprising tetrabasic zinc chloride and trimethylglycine | |
KR20090016733A (en) | Biologically active nanoparticles of a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same | |
CN111093604B (en) | Oral care compositions | |
US9005587B2 (en) | Anti-bacterial and mineralizing calcium phosphate compositions | |
CN108743424B (en) | Oral care composition for tooth remineralization | |
CN108289804A (en) | Metal amino acid complex for bacterial accumulation | |
EP3547989B1 (en) | Oral care composition | |
RU2426690C2 (en) | Biologically active nanoparticles of carbonate-substituted hydroxyapatite, method of their production and compositions that include them | |
EP3668478B1 (en) | Oral care composition | |
WO2020099068A1 (en) | Oral care composition | |
EP3542776B1 (en) | Metal-carbon structure hybrid formulation for dental use in the treatment of dental hypersensitivity, demineralisation and cavities | |
CN115177543B (en) | Antibacterial caries preventing composition containing L-lactate, oral care product and preparation method and application thereof | |
WO2007101511A2 (en) | Mouth and teeth cleaning and/or remineralization method | |
WO2024012854A1 (en) | Oral care composition | |
WO2024104743A1 (en) | Oral care composition | |
CN111714385A (en) | Formula and application of composite micro-nano particles | |
CN116981437A (en) | Oral care compositions | |
EA042242B1 (en) | ORAL CARE COMPOSITION | |
EA039452B1 (en) | Oral care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PERIPRODUCTS LTD, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GILLAM, DAVID G.;HILL, ROBERT;COLLINGS, ALAN J.;AND OTHERS;SIGNING DATES FROM 20121012 TO 20130426;REEL/FRAME:042416/0285 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |